Core Viewpoint - Varonis Systems, Inc. is facing a class action lawsuit alleging violations of the Securities Exchange Act of 1934, with claims that the company misrepresented its revenue outlook and growth potential during the class period from February 4, 2025, to October 28, 2025 [1][2]. Group 1: Allegations and Impact - The lawsuit claims that Varonis executives created a false impression of reliable revenue projections while downplaying risks associated with seasonality and macroeconomic factors [2]. - It is alleged that Varonis' optimistic reports regarding growth and sales effectiveness were misleading, as the company struggled to maintain its annual recurring revenue growth without high quarterly conversion rates [2]. - Following the release of disappointing third-quarter results on October 28, 2025, which led to a lowered full-year guidance, Varonis' stock price plummeted nearly 49% [3]. Group 2: Legal Process and Representation - Investors who purchased Varonis common stock during the class period can seek appointment as lead plaintiff in the class action lawsuit, representing the interests of all class members [4]. - The lead plaintiff will have the authority to select a law firm for litigation, and participation as lead plaintiff does not affect an investor's ability to share in any potential recovery [4]. Group 3: Firm Background - Robbins Geller Rudman & Dowd LLP is a leading firm in complex class action litigation, having recovered over $916 million for investors in 2025 alone, marking its fourth 1 ranking in the past five years [5]. - The firm has a strong track record, recovering a total of $8.4 billion for investors over the last five years, significantly more than any other law firm [5].

Core Viewpoint - Varonis Systems, Inc. is facing a securities class action lawsuit due to alleged failures in transitioning to a Software-as-a-Service (SaaS) model and undisclosed issues with renewal rates, leading to significant financial losses for investors [1]. Summary by Relevant Sections Lawsuit Details - The lawsuit claims that Varonis executives concealed significant renewal softness in its Federal vertical and legacy on-premises business while promoting a successful transition to SaaS [1]. - The litigation follows a disclosure on October 28, 2025, revealing a 63.9% year-over-year decline in term license revenue and a reduced Annual Recurring Revenue (ARR) outlook, resulting in a 48% stock crash, equating to a loss of approximately $3.8 billion in market value [1]. Financial Impact - Following the October 28 disclosure, Varonis shares plummeted from $63.00 to $32.34 in a single day, representing a nearly 50% loss in shareholder value [1]. - The company significantly reduced its Q4 revenue and full-year ARR guidance after missing expectations in Q3 [1]. Allegations of Misrepresentation - The lawsuit alleges that Varonis misrepresented its ability to convert existing customers from on-premises to SaaS, claiming they were "well on our way" to a SaaS future and that they had a "massive opportunity" to increase ARR from the existing customer base [1]. - It is claimed that the actual conversion potential was misrepresented, as the company struggled to convince on-premises users to migrate at the anticipated pace [1].

Core Viewpoint - A class action lawsuit has been filed against AMC Entertainment Holdings, Inc. regarding allegations of securities fraud and unlawful business practices related to AMC Preferred Equity Units (APEs) [1] Group 1: Class Action Details - The lawsuit concerns whether AMC and its officers engaged in misleading practices that affected APE holders, particularly those who held APEs before their conversion to common stock on August 25, 2023 [1] - Investors have until April 20, 2026, to request to be appointed as Lead Plaintiff if they purchased AMC securities during the Class Period [1] Group 2: Allegations Against AMC - The complaint alleges that AMC's statements were materially false and misleading, as the rights of APE holders were constrained by a technical loophole in the Certificate of Designations for AMC's preferred stock [1] - This loophole allowed AMC to exclude APE holders from receiving distributions after the conversion to common stock, which was not disclosed in public communications [1]

Core Viewpoint - A class action lawsuit has been filed against REGENXBIO Inc. regarding allegations of securities fraud and unlawful business practices following a significant drop in stock price due to FDA clinical holds on its gene therapies [1]. Group 1: Lawsuit Details - The class action lawsuit is focused on whether REGENXBIO and certain officers/directors engaged in securities fraud [1]. - Investors who purchased or acquired REGENXBIO securities during the Class Period have until April 14, 2026, to request appointment as Lead Plaintiff [1]. Group 2: FDA Clinical Holds - On January 28, 2026, REGENXBIO announced that the FDA placed a clinical hold on its investigational gene therapy RGX-111 for treating MPS I due to a case of neoplasm in a participant [1]. - The FDA also placed a clinical hold on RGX-121 for MPS II, citing similarities in products and shared risks between the studies [1]. Group 3: Stock Price Impact - Following the FDA announcement, REGENXBIO's stock price fell by $2.40 per share, or 17.9%, closing at $11.01 per share on January 28, 2026 [1].

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Navan, Inc. of Class Action Lawsuit and Upcoming Deadlines - NAVN Accessibility Statement Skip NavigationNEW YORK, March 5, 2026 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Navan, Inc. ("Navan" or the "Company") (NASDAQ: NAVN) and certain of its officers and/or directors, alleging violations of the federal securities laws. Such investors are advised to contact Danielle Peyto ...

Core Viewpoint - A class action lawsuit has been filed against uniQure N.V. due to allegations of securities fraud and unlawful business practices, following a significant drop in stock price after negative feedback from the FDA regarding its investigational gene therapy AMT-130 [1][1][1] Company Summary - uniQure N.V. is facing a class action lawsuit related to potential securities fraud involving its officers and directors [1] - The lawsuit is prompted by a press release from November 3, 2025, where uniQure announced that the FDA no longer believes that data from Phase I/II studies of AMT-130 may be adequate for a Biologics License Application (BLA) submission [1][1] - Following this announcement, uniQure's stock price fell by $33.40 per share, or 49.34%, closing at $34.29 per share [1][1][1] Industry Context - Pomerantz LLP, the law firm handling the class action, is recognized for its expertise in corporate, securities, and antitrust class litigation, having a history of recovering multimillion-dollar damages for victims of securities fraud [1][1]

Group 1 - Pomerantz LLP is investigating claims on behalf of investors of PROCEPT BioRobotics Corporation regarding potential securities fraud or unlawful business practices by the company and its officers [1] - On February 25, 2026, PROCEPT reported its fourth quarter 2025 financial results, revealing quarterly revenue that significantly missed analyst expectations [1] - The company reduced its full-year 2026 revenue guidance to a range of $390-$410 million, down from the previous range of $410-$430 million, citing disruptions from a realignment of its commercial organization and the elimination of bulk-purchasing discounts [1] Group 2 - Following the financial results announcement, PROCEPT's stock price dropped by $4.21 per share, or 15.12%, closing at $23.63 per share on February 26, 2026 [1] - Pomerantz LLP is recognized as a leading firm in corporate, securities, and antitrust class litigation, with a history of recovering multimillion-dollar damages for victims of securities fraud and corporate misconduct [1]

Core Viewpoint - CoreWeave, Inc. reported a Q4 2025 net loss of $452 million, nearly doubling Wall Street's estimated loss of $0.49 per share, leading to a significant drop in share price by nearly 20% [1][1][1] Financial Performance - The reported Q4 net loss was $452 million, or $0.89 per share, compared to the anticipated loss of $0.49 per share [1][1] - CoreWeave's Q1 2026 revenue guidance is projected to be between $1.9 billion and $2.0 billion, which is below the consensus estimate of $2.3 billion [1][1] Legal Issues - A securities class action lawsuit has been filed against CoreWeave and its executives, alleging operational failures and misrepresentation of scaling capabilities [1][1] - The lawsuit claims that CoreWeave violated the Securities Exchange Act of 1934, with specific allegations including share price erosion, single-supplier dependency, and concealing critical delays in their data center operations [1][1][1] Investor Actions - Investors who suffered losses during the class period (March 28, 2025, to December 15, 2025) have until March 13, 2026, to apply as Lead Plaintiff in the ongoing lawsuit [1][1]

Core Viewpoint - Institutional investors holding Snowflake Inc. (NYSE: SNOW) shares from June 27, 2023, to February 28, 2024, may face portfolio losses due to alleged securities fraud, prompting a potential class action lawsuit [1] Summary by Relevant Sections Institutional Holders - The stock price of Snowflake declined by $41.72 per share, or 18.14%, following corrective disclosures on February 28, 2024 [1] - The lawsuit claims that Snowflake and its officers made materially misleading statements regarding consumption patterns, product revenue growth, and the feasibility of a $10 billion revenue target for 2029 [1] - Institutional investors are encouraged to assess their options for recovery before the April 27, 2026, deadline for lead plaintiff appointment [1] Portfolio Impact Assessment - The lawsuit alleges that Snowflake's stock was artificially inflated due to positive statements about consumption stability and new product developments [1] - The company disclosed that FY '25 product revenue growth would only reach 22% year-over-year, significantly below the anticipated 30%, and withdrew its $10 billion target for 2029, leading to a repricing that affected all institutional holders who bought shares based on previous representations [1]

Core Viewpoint - Fermi Inc. is facing a securities class action lawsuit alleging misrepresentation regarding the demand for its Project Matador AI data center and the stability of its primary tenant, leading to significant stock price declines [1] Summary by Relevant Sections Allegations of Misrepresentation - The lawsuit claims that Fermi misrepresented the demand for Project Matador and the reliability of its anchor tenant, which was revealed when the first tenant terminated a $150 million Advance in Aid of Construction Agreement on December 12, 2025 [1] - Following this announcement, Fermi's stock price dropped nearly 34% in a single day [1] Class Action Details - The class action seeks to represent purchasers of Fermi Inc. common stock related to its October 2025 IPO and securities acquired between October 1, 2025, and December 11, 2025 [1] - The stock price fell to as low as $8.59 per share, marking a 59% decline from the IPO price of $21.00 per share [1] Concealed Risks and Overstatements - The complaint alleges that Fermi failed to disclose the extent to which Project Matador depended on a single tenant's funding commitment, posing a significant risk of termination [1] - It is also claimed that the IPO registration statement inflated the actual demand for Project Matador's capacity to attract higher valuations [1]